Qube Research & Technologies LTD Cellectis S.A. Transaction History

Qube Research & Technologies LTD

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$1.86 - $3.35 $372 - $670	-200 Reduced 64.1%	112 $0
Q1 2024 May 14, 2024	SELL	$2.41 - $3.09 $10,037 - $12,869	-4,165 Reduced 93.03%	312 $0
Q4 2023 Feb 13, 2024	BUY	$0.97 - $3.55 $4,303 - $15,751	4,437 Added 11092.5%	4,477 $13,000
Q3 2023 Nov 13, 2023	BUY	$1.58 - $2.86 $63 - $114	40 New	40 $0
Q4 2021 Feb 01, 2022	SELL	$8.01 - $12.84 $90,593 - $145,220	-11,310 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$11.94 - $16.09 $570,206 - $768,394	-47,756 Reduced 80.85%	11,310 $143,000
Q2 2021 Aug 13, 2021	BUY	$14.36 - $20.93 $104,267 - $151,972	7,261 Added 14.02%	59,066 $914,000
Q1 2021 May 14, 2021	BUY	$18.19 - $33.25 $780,732 - $1.43 Million	42,921 Added 483.13%	51,805 $1.05 Million
Q4 2020 Feb 16, 2021	BUY	$15.87 - $31.64 $140,989 - $281,089	8,884 New	8,884 $240,000

10.8M

5.9K

1.4K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $71M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.